AKT Isoform Activity Peptide Arrays
Official title: Development of AKT isoform activity peptide arrays
Funded at Roswell Park Cancer Institute Corp · NIH-11439936 · Data updated 2026-11-12
This grant aims to create peptide arrays that measure activity of AKT isoforms, which could help tailor cancer and metabolic disease treatments to individuals.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Roswell Park Cancer Institute Corp NIH-funded |
| Lab location | 1 site (Buffalo, United States) |
| Project start | September 1, 2026 |
| Project end | August 31, 2028 |
| Funding year | 2026 |
| Award (this year) | $477,125 |
| NIH project number | 1R21GM166621-01 |
| Project ID | NIH-11439936 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients with cancers or genetic syndromes linked to PI3K/AKT signaling who might benefit from isoform-specific therapies or improved diagnostic assays.
✕Less likely to help
Individuals without access to AKT-targeted therapies or those unlikely to be tested for AKT activity may see little direct benefit.
What this research studies
The project focuses on AKT signaling, a pathway involved in many cell processes and diseases. Researchers will develop peptide-based readouts to distinguish how different AKT isoforms behave in response to various signals. These arrays will enable clearer, cell-type-specific measurement of AKT activity and how it changes with inhibitors. The work could guide development of more precise therapies for conditions linked to PI3K/AKT signaling.
Why it matters
Potential benefit: If successful, patients could benefit from more accurate tests and better-targeted treatments that modulate AKT activity.
How similar studies have gone: Previous work has shown that isoform-specific signaling plays a role, but comprehensive isoform-selective substrates and cellular readouts remain underdeveloped, making this approach novel yet grounded in prior findings.
Where this research is happening
-
Roswell Park Cancer Institute Corp
Buffalo, United States Active
Researchers
- Principal investigator: Gelman, Irwin H. — Roswell Park Cancer Institute Corp
- Study coordinator: Gelman, Irwin H.
Related research
Other NIH-funded projects on the same topics.
-
A network for sharing data and resources in immuno-oncology.
This study is all about bringing together experts to find better ways to treat cancer by understanding why some treatments don’t work and discovering new targets for the immune system, which could lead to more personalized and effective therapies for adults.
-
A network for sharing data and resources in immuno-oncology
This study is all about finding better ways to treat cancer using the body's immune system by working together with different experts to share information, which could lead to new treatments and help patients like you have more effective options.
-
Targeting retrotransposons to help kids with hard-to-treat cancers like neuroblastoma
Aims to repurpose safe antiviral drugs to block retrotransposons in children with relapsed or refractory neuroblastoma to improve outcomes.
-
MedSupport: Helping families overcome barriers to kids' chemotherapy medicines
This program offers extra support to parents of children with acute lymphoblastic leukemia to help them give home chemotherapy medicines more reliably.
-
Innate immune cells and female lung cancer risk
A study exploring how certain immune cells in the lungs may contribute to lung cancer in young women who don’t smoke.
-
Effect of ONP filler materials on how fast nicotine is delivered
This grant tests how different filler materials in oral nicotine pouches affect how quickly nicotine is released and absorbed in the mouth.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.